Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,845 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy.
Nuciforo P, Thyparambil S, Aura C, Garrido-Castro A, Vilaro M, Peg V, Jimenez J, Vicario R, Cecchi F, Hoos W, Burrows J, Hembrough T, Ferreres JC, Perez-Garcia J, Arribas J, Cortes J, Scaltriti M. Nuciforo P, et al. Among authors: cortes j. Mol Oncol. 2016 Jan;10(1):138-147. doi: 10.1016/j.molonc.2015.09.002. Epub 2015 Sep 15. Mol Oncol. 2016. PMID: 26422389 Free PMC article.
Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.
Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, Bianchi G, Cortes J, McNally VA, Ross GA, Fumoleau P, Gianni L. Baselga J, et al. Among authors: cortes j. J Clin Oncol. 2010 Mar 1;28(7):1138-44. doi: 10.1200/JCO.2009.24.2024. Epub 2010 Feb 1. J Clin Oncol. 2010. PMID: 20124182 Free PMC article. Clinical Trial.
Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients.
Scaltriti M, Eichhorn PJ, Cortés J, Prudkin L, Aura C, Jiménez J, Chandarlapaty S, Serra V, Prat A, Ibrahim YH, Guzmán M, Gili M, Rodríguez O, Rodríguez S, Pérez J, Green SR, Mai S, Rosen N, Hudis C, Baselga J. Scaltriti M, et al. Among authors: cortes j. Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3761-6. doi: 10.1073/pnas.1014835108. Epub 2011 Feb 14. Proc Natl Acad Sci U S A. 2011. PMID: 21321214 Free PMC article.
Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer.
Cortés J, Fumoleau P, Bianchi GV, Petrella TM, Gelmon K, Pivot X, Verma S, Albanell J, Conte P, Lluch A, Salvagni S, Servent V, Gianni L, Scaltriti M, Ross GA, Dixon J, Szado T, Baselga J. Cortés J, et al. J Clin Oncol. 2012 May 10;30(14):1594-600. doi: 10.1200/JCO.2011.37.4207. Epub 2012 Mar 5. J Clin Oncol. 2012. PMID: 22393084 Clinical Trial.
2,845 results